Martin Nutraceuticals Inc. Announces Clinical Study Results for Anti-Oxidant Formula
Posted on: Tuesday, 15 March 2005, 09:00 CST
RENO, Nev., March 15, 2005 (PRIMEZONE) -- Martin Nutraceuticals Inc. is pleased to announce the clinical studies have been completed for its anti-oxidant formula. Furthermore, the anti-oxidant formula is being branded and unveiled as Oxygenol(tm).
The Martin Nutraceuticals anti-oxidant formula, Oxygenol(tm) is a water soluble, anti-oxidant formula extracted from a particular species of pine bark extract, high in bioflavonoids. These bioflavonoids are particularly favorable, due to their nature of blocking unwanted, undesirable compounds in the body. Being far more powerful than vitamin E and 20 times more powerful than vitamin C, this anti-oxidant formula has been a mainstay in the treatment of chronic illnesses including Chronic Fatigue Syndrome and Fibromyalgia.
Dr. A.W. Martin DC, Ph.D., RNCP, D.N.M., director of research for Martin Nutraceuticals Inc. is pleased to announce the results of a clinical study of Oxygenol(tm) on the symptoms of Chronic Fatigue Syndrome. Dr. Martin is a well-known and respected researcher and the author of the book "Chronic Fatigue Syndrome the Modern Woman's Curse."
Dr. Martin conducted a 50 case study of patients officially diagnosed with Chronic Fatigue Syndrome. Chronic Fatigue Syndrome is characterized by extreme fatigue lasting over 6 months with associated symptoms including: cognitive, sleep, and muscle dysfunction.
The 6 week study had all patients taking 200mg of Oxygenol(tm) daily. There was an 85% improvement in all symptoms of Chronic Fatigue Syndrome. Oxygenol(tm) is Martin Nutraceutical's proprietary blend of Pine Bark extract with other antioxidants.
Dr. Martin was thrilled with the results and believes that Oxygenol's(tm) ability to bring extra oxygen to the brain is one of the major reasons for the study's success.
Martin Nutraceuticals is extremely happy with the results provided by the newest product of the Martin health and wellness line. Oxygenol(tm) will be available shortly to customers in North America. For more information on Martin products and more detailed information on these clinical studies please visit: www.martinnutra.com or email at: info@martinnutra.com
Forward Looking Statements
The management of the company, who take full responsibility for its content, prepared this press release. Statements in this news release concerning the company's business outlook or future economic performance, anticipated profitability, revenues, expenses, or other financial items; and statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements" as that term is defined under the Federal Securities Laws. Forward-looking statements are subject to risks, uncertainties and other factors which could cause actual results to differ materially from those contained in such statements. Such risks, uncertainties and factors include, but are not limited to, future capital needs, changes and delays in product development plans and schedules, customer acceptance of new products, changes in pricing or other actions by competitors, and general economic conditions.
CONTACT: Martin Nutraceuticals Inc. 780-707-0587 www.martinnutra.com
Copyright © 2005 PrimeZone Media Network, Inc.
Source: PrimeZone Media Network
Related Articles
- Virus May Play Role In Chronic Fatigue Syndrome
- New Research Will Benefit Four Million Americans Suffering from Chronic Fatigue Syndrome
- Hemispherx Comments on Chronic Fatigue Syndrome Initiatives By the Centers for Disease Control
- Hemispherx Biopharma to Present at 8th International IACFS Conference on Chronic Fatigue Syndrome, Fibromyalgia, Related Illnesses; Successful Transfer of Technology to Expand Drug Production Announced
- Science News Cover Story Highlights Hemispherx Biopharma in New Insights Confronting Chronic Fatigue Syndrome; Promising Experimental Medicine is Designated First Specific Drug Candidate for CFS
- Hemispherx Biopharma to Present Audited Results of Ampligen(R) Clinical Trials on Chronic Fatigue Syndrome at 5th International Conference on HHV; Studies Show Medically Significant Improvements Among CFS Patients
- Treating and Beating Fibromyalgia and Chronic Fatigue Syndrome: A Manual for Non-Allopathic Doctors
- Hemispherx Biopharma's Investigational Drug Increases Physical Performance in New Chronic Fatigue Syndrome -CFS- Clinical Study; Maximum Oxygen Consumption Increased 10-Fold With Ampligen-R- Vs. Placebo
- Los Angeles Times Article Focuses on Hemispherx Biopharma's Experimental Drug Ampligen As a Potential New Therapy for Chronic Fatigue Syndrome
- The Psychopathology of Functional Somatic Syndromes: Neurobiology and Illness Behavior in Chronic Fatigue Syndrome, Fibromyalgia, Gulf War Illness, Irritable Bowel, and Premenstrual Dysphoria
 |
 |
User Comments (0)
RSS Feeds